CTYCity Therapeutics

US ExchangeHealth Care2026-10-16

Clinical-stage biotech developing next-gen RNAi therapeutics for thromboembolic diseases, Stargardt disease type 1, and anemia of chronic disease.

$—IPO price

—Raised

—Day-1 close

0.00%Day-1 return

Clinical-stage biotech developing next-gen RNAi therapeutics for thromboembolic diseases, Stargardt disease type 1, and anemia of chronic disease.

Company description (source: StockAnalysis)

City Therapeutics is a clinical-stage biotechnology company developing the next generation of RNA interference (“RNAi”) therapeutics designed to silence the expression of disease-relevant proteins, with the aim of delivering meaningful and durable benefits for patients in need. Our current pipeline is focused on indications with significant unmet medical need, including thromboembolic diseases, Stargardt disease type 1, and anemia of chronic disease, where we believe disease biology supports RNAi-mediated knockdown as a differentiated approach ...

生物医药RNA疗法临床阶段

51CFO read: Requires FDA late-stage clinical filing experience, RNAi platform financial modeling, and pipeline valuation expertise.

Management details per the SEC prospectus.

Company profile SEC prospectus

Does your company need this kind of CFO?

51CFO matches you with Western CFOs who have each run a full US IPO — plus other C-level talent. First shortlist within 48 hours; free 30-minute listing-readiness read.

Talk to us